10-Q: Myriad Genetics Q2 2026 Earnings: Revenue Decline, Strategic Investments

Myriad Genetics reports a revenue decrease in Q2 2026 driven by estimate changes and reimbursement pressures, while increasing sales and marketing investments.

Summary

• Myriad Genetics reported total revenue of $190.7 million for the three months ended June 30, 2026, a decrease of $22.4 million compared to the prior year period.
• The decrease in revenue was attributed to a $11.0 million reduction due to changes in estimates for cash collections and declines in reimbursement rates for Cancer Care Continuum and Prenatal Health tests.
• Cost of revenue increased by $2.4 million to $63.7 million, leading to a gross profit of $127.0 million, down from $151.8 million in the prior year.
• Operating expenses saw a significant increase, with Sales and Marketing expenses rising by $11.2 million to $83.1 million, while General and Administrative expenses decreased by $9.0 million.
• The company reported an operating loss of $38.9 million and a net loss of $43.2 million for the quarter.
• For the six months ended June 30, 2026, total revenue was $391.1 million, a decrease of $17.9 million year-over-year.
• Cash and cash equivalents decreased to $115.2 million from $149.6 million at the end of 2025, with $24.0 million used in operations and $9.7 million for investing activities during the first half of 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to declining revenues, increased operating expenses, and a net loss, despite some strategic product developments.

Positives

• Increased volume in Cancer Care Continuum (6% for Q2, 9% for H1) and Mental Health (4% for Q2, 5% for H1).
• Mental Health revenue increased by $6.3 million for the six months ended June 30, 2026, due to increased volume and revenue per test.
• General and Administrative expenses decreased by $9.0 million for the three months and $13.3 million for the six months ended June 30, 2026.
• The company remains in compliance with all applicable covenants under its Credit Agreement.
• Stockholders approved the 2026 Employee, Director and Consultant Equity Incentive Plan.
• The company launched Prolaris + AI, combining genomics and AI for prostate cancer treatment insights.
• Expanded availability of Precise MRD for colorectal, renal, and breast cancers with supporting data.

Negatives

• Total revenue decreased by $22.4 million for the three months ended June 30, 2026, compared to the prior year.
• Revenue per test declined in Cancer Care Continuum (15% for Q2) and Prenatal Health (8% for Q2).
• Prenatal Health revenue decreased by $7.8 million for the three months and $15.2 million for the six months ended June 30, 2026.
• Operating loss of $38.9 million for the three months and $69.6 million for the six months ended June 30, 2026.
• Net loss of $43.2 million for the three months and $77.3 million for the six months ended June 30, 2026.
• Cash and cash equivalents decreased by $34.4 million from December 31, 2025, to June 30, 2026.
• Goodwill impairment charge of $4.5 million recognized in the first quarter of 2026 for the Women's Health reporting unit.
• Increased interest expense due to the term loan secured in July 2025.

Risks

• Sales and profit margins of existing tests may decline.
• Inability to operate the business on a profitable basis.
• Failure to achieve revenue growth targets or generate sufficient revenue from new tests.
• Changes in government or private insurer coverage and reimbursement levels.
• Increased competition and development of new competing tests.
• Delays or problems with operating laboratory testing facilities.
• Public concern over genetic testing.
• Risks related to security breaches, loss of data, and cybersecurity incidents.

Future Outlook

The company plans to leverage its scientific foundation, clinical partnerships, and technology-enabled capabilities to expand adoption of its testing portfolio and integrate precision medicine solutions. The strategy focuses on providing a comprehensive testing menu for Cancer Care Continuum, growing Prenatal Health and Mental Health revenues, and delivering sustained profitable growth through financial and operational discipline.

Management Comments

• We believe there are significant growth opportunities in addressing the pressing healthcare needs of patient populations through innovative molecular diagnostic testing and precision medicine solutions and services.
• Our long-term growth strategy is built on leveraging our differentiated strengths, including our reputation for trusted high-quality tests and customer service, and our established, extensive commercial reach in community medicine.
• Our strategic intent is to accelerate profitable growth by focusing on (i) providing a comprehensive testing menu for the Cancer Care Continuum market with a priority for high growth applications; (ii) growing our Prenatal Health and Mental Health revenues at or above market growth; and (iii) delivering sustained profitable growth through financial and operational discipline and leveraging our operating model.
• We are committed to making molecular testing accessible and actionable for patients and providers while driving long-term growth and profitability.

Industry Context

StockSavvy.ai notes that Myriad Genetics' performance reflects broader industry trends in molecular diagnostics, including pressure on reimbursement rates and the need for continuous innovation. The company's strategic focus on specific market segments like Cancer Care Continuum and the integration of AI into diagnostic tools like Prolaris + AI align with industry advancements.

Comparison to Industry Standards

• The decline in revenue per test for Cancer Care Continuum and Prenatal Health aligns with industry-wide reimbursement pressures faced by many diagnostic companies.
• The increased investment in Sales and Marketing is a common strategy in the competitive diagnostics market to drive adoption of new and existing tests.
• The launch of Prolaris + AI positions Myriad Genetics alongside other companies integrating AI into healthcare solutions, a growing trend across the industry.

Management Changes

Legal Proceedings

• A qui tam complaint filed in November 2022 against Carolina Urology Partners, PLLC, and certain of its partners, as well as Myriad Genetics and certain former employees, alleging violations of the False Claims Act, was unsealed in January 2025. The government declined to intervene. The company's motion to dismiss was denied in part on July 9, 2026, and the litigation is ongoing.

Stakeholder Impact

• Shareholders may be impacted by the declining revenue, net loss, and goodwill impairment, potentially affecting share price.
• Employees may be impacted by the company's strategic investments in sales and marketing, and the overall financial performance.
• Healthcare providers and patients may benefit from the launch of new products like Prolaris + AI and expanded availability of Precise MRD.
• Third-party payors continue to exert pressure on reimbursement rates, impacting revenue.

Next Steps

• Continue to focus on providing a comprehensive testing menu for the Cancer Care Continuum market.
• Grow Prenatal Health and Mental Health revenues at or above market growth.
• Deliver sustained profitable growth through financial and operational discipline.
• Leverage scientific foundation, clinical partnerships, and technology-enabled capabilities to expand testing portfolio adoption.
• Integrate precision medicine solutions more deeply into clinical workflows.
• Continue to monitor for any additional indicators of goodwill impairment.

Key Dates

Recommendation

While the company faces revenue declines and net losses, it is making strategic investments in new products and sales/marketing. The ongoing litigation and reimbursement pressures present significant risks, but the company's focus on innovation and market expansion warrants a hold recommendation pending clearer signs of revenue recovery and profitability.

Keywords

molecular diagnostics, precision medicine, genetic testing, Cancer Care Continuum, Prenatal Health, Mental Health, prostate cancer, prognostic test